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Summary
Regadenoson is a new vasodilator myocardial stress
agent that is easier-to-use and more tolerable than ade-
nosine. We demonstrate that, in patients undergoing
cardiovascular magnetic resonance myocardial perfusion
imaging, regadenoson is safe and effective in producing
hyperemia and identifying the need for future
revascularization.
Background
Regadenoson (Lexiscan; Astellas) is a new vasodilator
myocardial stress agent that selectively activates the
A2A receptor. Unlike adenosine, regadenoson is easier
to administer and results in fewer side effects. Although
extensively studied in patients undergoing nuclear myo-
cardial perfusion imaging (MPI), its performance in car-
diovascular magnetic resonance (CMR) MPI remains
unknown. The aim of this study was to assess the safety
and tolerability of regadenoson and determine its ability
to produce hyperemia and predict subsequent coronary
revascularization in patients undergoing CMR-MPI.
Methods
120 patients were prospectively enrolled to receive
CMR-MPI (Achieva, Philips 1.5T) with regadenoson.
Patients with contraindications to CMR-MPI or regade-
noson were excluded. Short-axis slices were obtained at
three levels of the left ventricle (LV) during first pass of
Gadolinium-DTPA(0.075 mmol/kg at 4 ml/sec) for 50
consecutive heart beats. Images were acquired using a
hybrid gradient echo/echo planar imaging sequence.
Imaging was performed 1 minute after injection of rega-
denoson (0.4mg) and then repeated 15 minutes after
injection of aminophylline (125mg) under resting condi-
tions. Perfusion defects were defined as subendocardial
hypointensity in a coronary distribution at stress, invol-
ving ≥25% wall thickness, and persisting for ≥2h e a r t
beats following peak enhancement of the LV cavity. In a
subgroup of patients (n=99), custom software was used
to generate time intensity curves and to compare the
myocardial upslope of the midventricular slice during
stress and rest. All subjects were followed for 3 months
for the occurrence of coronary revascularization.
Results
Overall, 51/120 (43%) of patients were female with an
average age of 55±15 years and body mass index of 29
±6 kg/m2. Baseline patient characteristics include: cor-
onary artery disease (33%), diabetes (38%), hypertension
(56%), and hypercholesterolemia (95%). The average
resting blood pressure and heart rate were 124/
61mmHg and 70bpm, respectively. Peak heart rate after
regadenoson administration was 98bpm (p<0.001). Most
patients (87%) experienced side effects from regadeno-
son including shortness of breath (34%), flushing (23%),
and chest discomfort (17%). No EKG changes or resi-
dual side effects persisted in any patient at completion
of study. The average myocardial upslope increased sig-
nificantly between rest and stress conditions (9.1±5.9 vs.
12.8±8.1, p<0.001), reflecting the expected hyperemic
effect of regadenoson. Perfusion defects were visually
apparent in 33/120 (28%) patients. Revascularization
occurred in 8/120 (7%) patients (Figure 1). The presence
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any medium, provided the original work is properly cited.of a perfusion defect significantly predicted future revas-
cularization (Figure 2). Only 1 patient without a perfu-
sion defect was revascularized within the follow-up
period.
Conclusions
Regadenoson is safe, easy-to-use, and effective in produ-
cing hyperemia and identifying need for future revascu-
larization in patients undergoing CMR-MPI.
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Figure 1 Patient with perfusion defect in inferior and inferior-lateral myocardial wall undergoing regadenoson CMR-MPI and subsequent cardiac
catheterization of right coronary artery.
Figure 2 Cumulative incidence of coronary revascularization in
patients with and without perfusion defects undergoing
regadenoson CMR-MPI.
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